Cantor Fitzgerald Reiterates Overweight on VolitionRX, Maintains $2.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating on VolitionRX (AMEX:VNRX) and maintained a $2.5 price target.
March 27, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald maintains an Overweight rating on VolitionRX with a $2.5 price target.
The reiteration of an Overweight rating by a reputable analyst firm like Cantor Fitzgerald, along with a maintained price target, suggests a positive outlook on the stock. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100